Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established

Blood

Volumn 89, Issue 12, 1997, Pages 4425-4436

  Vitetta, Ellen S ^a   Tucker, Thomas F ^b   Racila, Emilian ^b   Huang, Yi Wu ^b   Marches, Radu ^b   Lane, Nancy ^b   Scheuermann, Richard H ^b   Street, Nancy E ^b   Watanabe, Takeshi ^b   Uhr, Jonathan W ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANIMAL CELL; ANTIBODY TITER; ARTICLE; CELL DIVISION; CELL GROWTH; GENE MUTATION; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SPLENOMEGALY; TUMOR GROWTH;

EID: 0030912221     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4425     Document Type: Article

References (85)

1. Stewart THM, Hollinshead AC, Raman S: Tumor dormancy initiation, maintenance and termination in animals and humans. Can J Surg 34:321, 1991
2. Meltzer A: Dormancy and breast cancer. J Surg Oncol 43:181, 1990
3. Demicheli R: Tumor dormancy and metastasis development in operable breast cancer: Data from clinical trials, in Yefenof E, Scheuermann RH (eds): Premalignancy and Tumor Dormancy. Georgetown, TX, RG Landes, 1996, p 181
4. Hadfield G: The dormant cancer cell. Br Med J 2:607, 1954
5. Wheelock EF, Weinhold KJ, Levich J: The tumor dormant state. Adv Cancer Res 34:107, 1981
6. Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, Uhr JW: Immunotoxins: A new approach to cancer therapy. Science 219:644, 1983
7. Slavin S, Strober S: Spontaneous murine B-cell leukaemia. Nature 272:624, 1978
8. 1, a murine model for chronic lymphocytic leukemia: Use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev 48:81, 1979
9. 1). I. Cell surface expression of IgM, IgD, Ia, and FcR. J Immunol 123:992, 1979
10. Racila E, Scheuermann RH. Picker LJ, Yefenof E, Tucker T, Chang W, Marches R, Street NE, Vitetta ES, Uhr JW: Tumor dormancy and cell signalling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 181:1539, 1995
11. 1 lymphoma. Cancer Res 51:5045S, 1991
12. Yefenof E, Picker LJ, Scheuermann RH, Tucker TF, Vitetta ES, Uhr JW: Cancer dormancy: Isolation and characterization of dormant lymphoma cells. Proc Natl Acad Sci USA 90:1829, 1993
13. Stevenson GA, Stevenson FK: Prospects for the treatment of B cell tumors using idiotypic vaccination. Int Rev Immunol 4:271, 1989
14. Stevenson FK, Stevenson GA, Glennie MJ: Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol 48:126, 1990
15. Hoggenraad NJ, Wraight CJ: The effect of pristane on ascites tumor formation and monoclonal antibody production. Methods Enzymol 121:375, 1986
16. Lacy MJ, Voss EW Jr: A method to induce immune polyclonal ascites fluid in BALB/c mice using Sp2/0-Ag14 cells. J Immunol Methods 87:169, 1986
17. Yagawa K, Vitetta ES: Induction of proliferation and differentiation of murine B cells bearing surface Ig lambda by rat monoclonal antibody to lambda chain. Hybridoma 2:169, 1983
18. Yuan D, Vitetta ES, Kettman JR: Cell surface immunoglobulin. XX. Antibody responsiveness of subpopulations of B lymphocytes bearing different isotypes. J Exp Med 145:1421, 1977
19. Fukuda T, Kitamura D, Taniuchi I, Maekawa Y, Benhamou LE, Sarthou P, Watanabe T: Restoration of surface IgM-mediated apoptosis in an anti-IgM-resistant variant of WEHI-231 lymphoma cells by HS1, a protein-tyrosine kinase substrate. Proc Natl Acad Sci USA 92:7302, 1995
20. Benhamou LE, Watanabe T, Kitamura D, Cazenave P-A, Sarthou P: Signaling properties of anti-immunoglobulin - Resistant variants of WEHI-231 B lymphoma cells. Eur J Immunol 24:1993, 1994
21. Yamanashi Y, Okada M, Semba T, Yamori T, Umemori H, Tsunasawa S, Toyoshima K, Kitamura D, Watanabe T, Yamamoto T: Identification of HS1 protein as a major substrate of proteintyrosine kinase(s) upon B-cell antigen receptor-mediated signaling. Proc Natl Acad Sci USA 90:3631, 1993
22. Terstappen LWMM, Mickaels R, Dost R, Loken MR: Increased light scattering resolution facilitates multidimensional flow cytometric analysis. Cytometry 11:506, 1990
23. Sambrook J, Fritsch EF, Mariatis T: Molecular Cloning, A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
24. Scheuermann RH, Racila E, Tucker T, Yefenof E, Street N, Vitetta E, Picker L, Uhr J: Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells. Proc Natl Acad Sci USA 91:4048, 1994
25. c-src-specific tyrosine kinase activity. Proc Natl Acad Sci USA 83:852, 1986
26. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658, 1985
27. Levy R, Miller RA: Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst 10:61, 1990
28. Taya M, Haimovich J: Immunotherapy of B lymphoma by anti-idiotype antibodies: Characterization of variant tumor cells appearing a long time after the initial tumor inoculation. Cancer Immunol Immunother 34:43, 1991
29. Roth MS, Weiner GJ, Allen EA, Terry VH, Harnden CE, Boehnke M, Kaminski MS, Ginsburg, D: Molecular characterization of anti-idiotype antibody-resistant variants of a murine B cell lymphoma. J Immunol 145:768, 1990
30. Weiner GJ, Kaminski MS: Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma. J Immunol 144:2436, 1990
31. DeFranco AL: Transmembrane signaling by antigen receptors of B and T lymphocytes. Curr Opin Cell Biol 7:163, 1995
32. Kitamura D, Kaneko H, Taniuchi I, Akagi K, Yamamura K, Watanabe T: Molecular cloning and characterization of mouse HS1. Biochem Biophys Res Commun 208:1137, 1995
33. Levy R, Miller AR: Therapy of lymphoma directed at idiotypes. Monogr J Natl Cancer Inst 10:61, 1990
34. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651, 1989
35. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA: Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13:444, 1992
36. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B: Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease. Blood 78:3021, 1991
37. Van Dongen JJM, Breit TM, Adriaansen HJ, Keishuizen A, Hooijkaas H: Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 6:47, 1992
38. Estrov Z, Ouspenskaia MV, Felix EA, McClain KL, Lee M, Harris D, Pinkel DP, Zipf TF: Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 8:46, 1994
39. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Ferrant JL, Michaux JL, Martial P: Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clongeneic IgH probes and the polymerase chain reaction. Blood 82:1618, 1993
40. Brisco MJ, Condon J, Hughes E, Neoh S, Sykes PJ, Seshadri R, Toogood I, Wataers K, Tauro G, Ekert H, Morley AA: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343:196, 1994
41. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G: Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 323:448, 1990
42. Biondi A, Yokota S, Hansen-Hagge T, Rossi V, Giudici G, Maglia O, Basso G, Tell C, Masera G, Bartram C: Minimal residual disease in childhood acute lymphoblastic leukemia: Analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 6:282, 1992
43. Cave H, Guidal C, Rohrlich P, Delfau MH, Broyait A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Grandchamp B: Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 83:1892, 1994
44. Talpaz M, Estrov H, Kantarjian H, Ku S, Foteh A, Kurzrock R: Persistence of dormant leukemic progenitors during interferoninduced remission in chronic myelogenous leukemia. J Clin Invest 94:1383, 1994
45. Henderson JC, Harris JR, Kinne DW, Hellman S: Cancer of the breast, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, p 1201
46. Cooke MP, Heath AW, Shokat KM, Zeng Y, Finkelman FD, Linsley PS, Howard M, Goodnow CC: Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 179:425, 1994
47. Cyster JG, Hartley SG, Goodnow CC: Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371:389, 1994
48. Eris JM, Basten A, Brink R, Doherty K, Kehry MR, Hodgkin PD: Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci USA 91:4392, 1994
49. Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hsueh R, Vitetta ES, Scheuermann RH, Uhr JW: Tumor dormancy and cell signalling. Ill: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol 2:125, 1996
50. Knittler MR, Haas IG: Interaction of BIP with newly synthesized immunoglobulin light chain molecules: Cycles of sequential binding and release. EMBO J 11:1573, 1992
51. Taniuchi I, Kitamura D, Maekawa Y, Fukuda T, Kishi H, Watanabe T: Antigen-receptor induced clonal expansion and deletion of lymphocytes are impaired in mice lacking HS1 protein, a substrate of the antigen-receptor-coupled tyrosine kinases. EMBO J 14:3664, 1995
52. Desiderio SV: B-cell activation. Curr Opin Immunol 4:252, 1992
53. Gambier JC, Bedzyk W, Campbell K, Chien N, Friedrich J, Harwood A, Jensen W, Pleiman C, Clark MR: The B cell antigen receptor: Structure and function of primary, secondary, tertiary and quaternary components. Immunol Rev 132:107, 1993
54. Kim K-M, Alber G, Weiser P, Reth M: Signaling function of the B-cell antigen receptors. Immunol Rev 132:125, 1993
55. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors. Cell 76:263, 1994
56. Gold MR, DeFranco AL: Biochemistry of B lymphocyte activation. Adv Immunol 55:221, 1994
57. Nagai K, Takata M, Yamamura H, Kurosaki T: Tyrosine phosphorylation of She is mediated through Lyn and Syk in B cell receptor signaling. J Biol Chem 270:6824, 1995
58. Burg DL, Furlong MT, Harrison ML, Geahlen RL: Interactions of Lyn with the antigen receptor during B cell activation. J Biol Chem 269:28136, 1994
59. Aoki Y, Kim Y-T, Stillwell R, Kim TJ, Pillai S: The SH2 domains of Src family kinases associate with Syk. J Biol Chem 270:15658, 1995
60. Sidorenko SP, Law C-L, Chandran KA, Clark EA: Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein. Proc Natl Acad Sci USA 92:359, 1995
61. Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC: Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med 182:1815, 1995
62. 2+ mobilization through distinct pathways. EMBO J 13:1341, 1994
63. Kurosaki T, Takata M, Yamanashi U, Inazu T, Taniguchi T, Yamamoto T, Yamamura H: Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med 179:1725, 1994
64. Flück M, Zürcher G, Andres A-C, Ziemiecki A: Molecular characterization of the murine Syk protein tyrosine kinase cDNA, transcripts and protein. Biochem Biophys Res Commun 213:273, 1995
65. ++ mobilization through distinct pathways. EMBO J 13:1341, 1994
66. Fischer G, Kent SC, Joseph L, Green DR, Scott DW: Lymphoma models for B cell activation and tolerance. X. Anti-mumediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc. J Exp Med 179:221, 1994
67. Lazarus AH, Kawauchi K, Rapoport MJ, Delovitch TL: Antigen-induced B lymphocyte activation involves the p21ras and ras.-GAP signaling pathway. J Exp Med 178:1765, 1993
68. Harwood AE, Gambier JC: B cell antigen receptor crosslinking triggers rapid protein kinase C independent activation of p21ras1. J Immunol 151:4513, 1993
69. 1. Cell Growth Differ 6:51, 1995
70. Hempel WM, Schatzman RC, DeFranco AL: Tyrosine phosphorylation of phospholipase C-gamma 2 upon cross-linking of membrane Ig on murine B lymphocytes. J Immunol 148:3021, 1992
71. 2+ in B lymphocytes. J Cell Biol 82:755, 1979
72. ++ stores in B lymphocytes. J Immunol 137:708, 1986
73. Wilson HA, Greenblatt D, Poenie M, Finkelman FD, Tsien RY: Crosslinkage of B lymphocyte surface immunoglobulin by antiIg or antigen induces prolonged oscillation of intracellular ionized calcium. J Exp Med 166:601, 1987
74. Choquet D, Ku G, Cassard S, Malissen B, Korn H, Fridman WH, Bonnerot C: Different patterns of calcium signaling triggered through two components of the B lymphocyte antigen receptor. J Biol Chem 269:6491, 1994
75. Takata M, Homma Y, Kurosaki T: Requirement of phospholipase C-γ2 activation in surface IgM-induced B cell apoptosis. J Exp Med 182:907, 1995
76. Vuist WMJ, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. Blood 83:899, 1994
77. Kwak LW, Campbell MJ, Czenvinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
78. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R: Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann NY Acad Sci 690:385, 1993
79. 1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol 137:1376, 1986
80. 1 leukemia by allogeneic bone marrow transplantation. J Immunol 130:2452, 1983
81. Weiss L, Reich S, Slavin S: The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia. Bone Marrow Transplant 16:457, 1995
82. 1 lymphoma. Cancer Res 54:2973, 1994
83. 1). Int J Cancer 65:204, 1996
84. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
85. Vitetta ES, Uhr JW: Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy. Cancer Res 54:5301, 1994